Cadrenal Therapeutics, Inc. (CVKD) is a late-stage biopharmaceutical company developing therapies for cardiovascular and thrombotic conditions. Coverage is thin: data aggregators drawing on S&P Global report roughly three current analyst price targets in the $12 to $17 range, averaging about $14, with a "Strong Buy" tilt. The single most clearly identified figure is a $13 target from H.C. Wainwright (analyst Joseph Pantginis), cut from $32 in early April 2026 to reflect an updated share count, financing needs, and the incorporation of CAD-1005 into the firm's model.
Because only a handful of analysts cover the name, the $14 mean should be read as a rough benchmark rather than a reliable consensus. Several aggregators still display older, pre-collapse targets well above $20, but these have not caught up with the share price and were excluded as stale. Analyst reasoning centers almost entirely on the clinical and regulatory path for CAD-1005 rather than near-term financials.
Shares trade near $1.00, leaving the stock at the low end of a 52-week range of roughly $1.76 to $14.64. Reaching the $14 central target implies an upside of roughly 1,300%, an extraordinarily large move by any standard. Such a repricing would likely require the company to advance its lead program successfully into late-stage development and secure meaningful non-dilutive funding, effectively re-rating a micro-cap that has lost most of its market value over the past year amid repeated equity financings.
The company is pre-revenue, so there is no earnings stream to bridge the gap; any move toward the target would be event-driven rather than gradual fundamental compounding.
The primary catalyst is clinical: Cadrenal completed an End-of-Phase 2 meeting with the FDA to align on a Phase 3 registrational path for CAD-1005, an anticoagulant candidate. Positive regulatory clarity, a well-designed Phase 3 trial, and subsequent positive data would be the clearest drivers of a re-rating. Additional factors include a stabilization of the capital structure, reduced financing overhang, and renewed institutional interest in a name with a meaningful unmet-medical-need story in thrombotic and cardiovascular conditions.
The obstacles are substantial. The company generates no product revenue and relies on equity raises to fund development, a pattern that has diluted shareholders and driven the price sharply lower. A Nasdaq minimum-bid-price deficiency or further reverse-stock-split or financing activity could keep the share price depressed. Clinical development is inherently binary: a Phase 3 delay, safety signal, or failure would materially undermine the entire investment thesis, and the $14 mean could become irrelevant if the capital structure changes again.
With the stock trading near multi-year lows, meaningful technical reference points are limited. The prior 52-week low area near $1.76 sits above the current price and would act as overhead resistance on any recovery, followed by psychological whole-dollar levels. The stock's prolonged downtrend and wide spread between the current price and the analyst range mean conventional support and resistance zones provide little insight into a move of the magnitude required to reach $14.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts' assumptions can differ, and H.C. Wainwright's target has already been revised sharply downward once this year. Key items to watch include updates on the Phase 3 design and initiation for CAD-1005, the next quarterly earnings and accompanying cash-runway commentary, any new financing or reverse-split announcements, FDA interactions, and analyst target revisions. Each can quickly reset the entire target range given the company's small market value.
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a low-priced, high-volatility name like CVKD, such tools can help traders surface opportunities, monitor open positions, and spot shifts in trend more efficiently than manual scanning. Traders interested in automating this process can explore the signals as part of a broader, data-informed routine.
The $14 central target is the average of a small group of current analyst price targets ranging from about $12 to $17, with H.C. Wainwright's $13 the most identifiable. It is a valid, real objective, but it sits roughly 1,300% above the present price, making it an exceptionally ambitious benchmark rather than a near-term expectation. The path hinges almost entirely on CAD-1005's regulatory and clinical progress plus the company's ability to fund itself without further eroding shareholder value. The thin coverage, wide range, and binary nature of clinical development argue for caution in treating $14 as predictive. Investors should monitor Phase 3 planning, financing activity, and analyst revisions for the next clues on whether the target remains realistic.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that CVKD and RADX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVKD and RADX's prices will move in lockstep.
| Ticker / NAME | Correlation To CVKD | 1D Price Change % | ||
|---|---|---|---|---|
| CVKD | 100% | +8.65% | ||
| RADX - CVKD | 31% Poorly correlated | -10.37% | ||
| GDTC - CVKD | 29% Poorly correlated | +0.03% | ||
| VIR - CVKD | 27% Poorly correlated | +2.00% | ||
| ARTV - CVKD | 26% Poorly correlated | +0.24% | ||
| ABUS - CVKD | 26% Poorly correlated | -3.00% | ||
More | ||||